key: cord-1006078-bqil3qun
authors: Barrière, Jérôme; Bondouy, Michaël
title: COVID arm and PET/FDG imaging
date: 2021-05-07
journal: Bull Cancer
DOI: 10.1016/j.bulcan.2021.04.002
sha: 223ca6971020485c8d1548319a79a6ebf2cbee43
doc_id: 1006078
cord_uid: bqil3qun

nan

COVID arm and PET/FDG imaging As stated at the start of the anti-SARS-CoV-2 vaccination campaign, all patients followed in oncology must be able to benefit from an anti-COVID vaccination as a priority, regardless of the nature of their neoplasia [1, 2] . Taking into account the regular follow-up of patients treated for cancer in the active phase of treatment with positron emission CT scan with F-FDG (PET/FDG), we report the case of a locoregional inflammatory reaction to be known by clinicians. A 76-year-old female patient undergoing treatment for a recurrent ovarian neoplasia previously treated for 4 cycles of CAR-BOPLATINE GEMCITABINE and BEVACIZUMAB underwent a PET/ FDG in early February 2021 for reassessment. While imaging demonstrated a complete metabolic response to the peritoneal targets initially present, hypermetabolism was noted in the right deltoid muscle with a standardized uptake value (SUV) of 4.3 associated with a hypermetabolic lymphadenopathy with SUV of 7.1 (figure 1). The patient had actually been vaccinated with a second dose of COMIRNATY® (Pfizer/BioNTech) five days previously. On examination, inflammatory edema in the deltoid was noted, mildly painful with no rash, associated with a 2 cm painless lymphadenopathy in the axillary. The patient did not report any fever for the days following the vaccination and the clinical examination normalized a few days later. Vaccination is known to cause transient inflammation of lymph nodes inducing positive findings on F-FDG PET scans with for instance flu vaccine [3] or human papillomavirus vaccines [4] . Considering the high immunogenicity of anti-SARS-CoV-2 vaccines, clinicians should be aware of local benign and transient side effects in order to avoid invasive diagnostic procedures. We must inform patients of the possibility of an inflammatory lymph node reaction following the anti-COVID vaccination and clinicians need to reassure them that there is no risk of cancer stimulation, especially women undergoing follow-up for breast cancer. Finally, we consider that SARS-CoV-2 vaccination should be avoided on the side of a recently treated breast tumor to avoid the risk of lymphedema. In case of an evolutive loco-regional breast cancer, PET/FDG could lead to the wrong conclusion of tumor progression. BULCAN-1106 Letter to the Editor Bull Cancer 2020; //: /// en ligne sur / on line on www.em-consulte.com/revue/bulcan www.sciencedirect.com

We must respect the anti-SARS-CoV-2 vaccine schedule without delay in cancer patients under treatment

Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine

Lymph node activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses

Jérôme Barrière 1 , Michaël Bondouy 2

avenue Maurice-Donat, 06250 Mougins, France Correspondence: Jérôme Barrière

Disclosure of interest: the authors declare that they have no competing interest.